



## **Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference**

March 6, 2018

CINCINNATI--(BUSINESS WIRE)--Mar. 6, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cowen 38<sup>th</sup> Annual Health Care Conference on Monday, March 12, 2018 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Hoffman will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>.

### **About Aerpio Pharmaceuticals**

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit [www.aerpio.com](http://www.aerpio.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180306005654/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investor:  
Aerpio Pharmaceuticals, Inc.  
Michael Rogers, CFO  
513-985-1958